HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Public ClinicalTrials.gov record NCT02793544. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Study identification
- NCT ID
- NCT02793544
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- Busulfan Drug
- Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5 Drug
- Cyclophosphamide 50mg/kg/day IV on Days -2,-1 Drug
- Cyclophosphamide 50mg/kg/day IV on Days -5,-4 Drug
- Fludarabine Drug
- G-CSF Drug
- Infusion of non-T-cell depleted bone marrow on Day 0 Procedure
- Mycophenolate mofetil Drug
- Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4 Drug
- Post-HCT Mesna Drug
- Pre-HCT Mesna on Days -2 and -1 Drug
- Pre-HCT Mesna on Days -5 and -4 Drug
- Pre-HCT Mesna on Days -6 and -5 Drug
- Sirolimus Drug
- Total Body Irradiation (TBI) 200cGy on Day -1 Radiation
- Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1 Radiation
Drug · Procedure · Radiation
Eligibility (public fields only)
- Age range
- 15 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2016
- Primary completion
- Feb 29, 2020
- Completion
- Feb 29, 2020
- Last update posted
- Aug 5, 2025
2016 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Shands HealthCare & University of Florida | Gainesville | Florida | 32610 | — |
| University of Miami | Miami | Florida | 33136 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| University of Maryland Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Memorial Sloan Kettering Cancer Center - Adults | New York | New York | 10065 | — |
| University of North Carolina Hospitals | Chapel Hill | North Carolina | 27599 | — |
| Ohio State Medical Center, James Cancer Center | Columbus | Ohio | 43210 | — |
| Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program | Richmond | Virginia | 23298 | — |
| Froedtert Memorial Lutheran Hospital | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02793544, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02793544 live on ClinicalTrials.gov.